<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="2877"><DrugName>TGP-580</DrugName><DrugSynonyms><Name><Value>CS-23</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TGP-580</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>hbFGF, Takeda</Value></Name></DrugSynonyms><CompanyOriginator id="20300">Takeda Pharmaceutical Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="20300">Takeda Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2877" type="Drug"><TargetEntity id="201518" type="siDrug">TGP-580</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"></TargetEntity><TargetEntity id="D019636" type="MeSH"></TargetEntity><TargetEntity id="-1502359765" type="omicsDisease"></TargetEntity><TargetEntity id="160" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="258" type="ciIndication"><TargetEntity id="K27" type="ICD10"></TargetEntity><TargetEntity id="10034341" type="MEDDRA"></TargetEntity><TargetEntity id="D010437" type="MeSH"></TargetEntity><TargetEntity id="-1581037299" type="omicsDisease"></TargetEntity><TargetEntity id="409" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00741" type="ciTarget"><TargetEntity id="29700784322473" type="siTarget">Fibroblast growth factor 2</TargetEntity><TargetEntity id="259" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="233">Neurodegenerative disease</Indication><Indication id="258">Peptic ulcer</Indication><Indication id="347">Wound healing</Indication></IndicationsSecondary><ActionsPrimary><Action id="3617">FGF-2 ligand</Action></ActionsPrimary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2017-09-02T11:00:37.000Z</LastModificationDate><ChangeDateLast>2004-10-05T11:08:47.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Takeda has discontinued developing &lt;ulink linkID="2877" linkType="Drug"&gt;TGP-580&lt;/ulink&gt;, a modified basic fibroblast growth factor (bFGF) for the potential treatment of peptic ulcers [&lt;ulink linkID="422782" linkType="reference"&gt;422782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;It entered phase II trials in both the US and Europe in 1995 [&lt;ulink linkID="189161" linkType="reference"&gt;189161&lt;/ulink&gt;] which demonstrated the therapeutic effect of &lt;ulink linkID="2877" linkType="Drug"&gt;TGP-580&lt;/ulink&gt; on NSAID-induced duodenal but not gastric injury. Its good tolerance and lack of systemic absorption or toxicity was also demonstrated [&lt;ulink linkID="272136" linkType="reference"&gt;272136&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;bFGF has been under consideration for the treatment of chronic and acute wounds for some time. In support of these indications there exist much data from cell culture investigations for the main cell types involved in healing to suggest a positive effect clinically. Some in vivo studies in acute wounds further suggest potential for bFGF, but to date this has not been translated into a significant effect in chronic wounds clinically.&lt;/para&gt;&lt;para&gt;The data in support of bFGF for brain disease mirror to a large extent early studies related to wound healing. bFGF and in some cases its analog, &lt;ulink linkID="2877" linkType="Drug"&gt;TGP-580&lt;/ulink&gt; have been shown to promote survival of cultivated brain cells isolated from all regions of the brain of embryonic rats and postnatal animals [&lt;ulink linkID="39580" linkType="reference"&gt;39580&lt;/ulink&gt;], [&lt;ulink linkID="39582" linkType="reference"&gt;39582&lt;/ulink&gt;], [&lt;ulink linkID="39602" linkType="reference"&gt;39602&lt;/ulink&gt;]. The effects of bFGF appear to be concentration-dependent [&lt;ulink linkID="39582" linkType="reference"&gt;39582&lt;/ulink&gt;], greater than those of acidic FGF [&lt;ulink linkID="39601" linkType="reference"&gt;39601&lt;/ulink&gt;] and include stimulation of nerve growth factor secretion [&lt;ulink linkID="39608" linkType="reference"&gt;39608&lt;/ulink&gt;]. Neurotrophic effects appear to be mediated through receptor protein kinase activation in a similar fashion to effects in other cell types [&lt;ulink linkID="39600" linkType="reference"&gt;39600&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo, bFGF activity and mRNA are seen in brain tissue traumatized by transient ischemia suggesting a role in repair. Other effects in vivo following treatment with bFGF include thalamic protection following cortical infarction and restoration of memory and learning ability in forebrain-lesioned mice [&lt;ulink linkID="39604" linkType="reference"&gt;39604&lt;/ulink&gt;], [&lt;ulink linkID="18261" linkType="reference"&gt;18261&lt;/ulink&gt;], [&lt;ulink linkID="39603" linkType="reference"&gt;39603&lt;/ulink&gt;], [&lt;ulink linkID="39593" linkType="reference"&gt;39593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="2877" linkType="Drug"&gt;TGP-580&lt;/ulink&gt; is recombinant human bFGH in which Cys-70 and Cys-88 are substituted with serine. These substitutions make it more stable in acidic conditions without affecting its biological activity [&lt;ulink linkID="39582" linkType="reference"&gt;39582&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="258">Peptic ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-11T00:00:00.000Z</StatusDate><Source id="422782" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="258">Peptic ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-11T00:00:00.000Z</StatusDate><Source id="422782" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="347">Wound healing</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-11T00:00:00.000Z</StatusDate><Source id="422782" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-11T00:00:00.000Z</StatusDate><Source id="422782" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="258">Peptic ulcer</Indication><Source id="189161" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="258">Peptic ulcer</Indication><Source id="189161" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="347">Wound healing</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00741"><Name>FGF-2 ligand</Name><SwissprotNumbers><Swissprot>P03969</Swissprot><Swissprot>P09038</Swissprot><Swissprot>P12226</Swissprot><Swissprot>P13109</Swissprot><Swissprot>P15655</Swissprot><Swissprot>P20003</Swissprot><Swissprot>P48798</Swissprot><Swissprot>P48799</Swissprot><Swissprot>P48800</Swissprot><Swissprot>Q60487</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2162364" number="EP-00281822" title="Polypeptide, DNA and its use"></PatentFamily><PatentFamily id="2200104" number="WO-09607421" title="An antiulcer medicine comprising a protein possessing cell growth factor activity and a proton pump inhibitor."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>